Interest in the glycerophosphoinositols has been increasing recently, on the basis of their biological activities. The cellular metabolism of these water-soluble bioactive phosphoinositide metabolites has been clarified, with the identification of the specific enzyme involved in their synthesis, PLA 2 IVα (phospholipase A 2 IVα), and the definition of their phosphodiesterase-based catabolism, and thus inactivation. The functional roles and mechanisms of action of these compounds have been investigated in different cellular contexts. This has led to their definition in the control of various cell functions, such as cell proliferation in the thyroid and actin cytoskeleton organization in fibroblasts and lymphocytes. Roles for the glycerophosphoinositols in immune and inflammatory responses are also being defined. In addition to these physiological functions, the glycerophosphoinositols have potential anti-metastatic activities that should lead to their pharmacological exploitation.
Introduction
The glycerophosphoinositols are active phosphoinositide metabolites that are derived via the action of PLA 2 (phospholipase A 2 ) on membrane phosphoinositides, and in particular from the activation of PLA 2 IVα [1] [2] [3] [4] [5] (Figure 1 ). Their formation is concomitant with that of the lysophospholipids, arachidonic acid, and the metabolites of the cyclo-oxygenase and lipoxygenase pathways [5] [6] [7] . Thus the activation of PLA 2 IVα leads to the simultaneous formation of a number of diverse lipid-derived messengers that can activate different functions in the cell, and that can also serve as feedback regulators of the very same pathways (P. Zizza, unpublished work, and see below). The physiological roles of all of these phosphoinositide and arachidonic acid metabolites have been studied extensively, although the cross-regulation and intracellular balance of the different lipid pools remain to be fully defined.
Similar to the inositol phosphates that are derived from phospholipase C activity on the membrane phosphoinositides, and due to their hydrophilic nature, the glycerophosphoinositols can diffuse rapidly throughout the cell, to exert their actions on specific targets in different cellular compartments. Again, as with the inositol phosphates, the glycerophosphoinositols are present in various phosphorylated forms that determine their differential Key words: actin cytoskeleton, cancer, cell proliferation, glycerophosphoinositol, lipid signalling, phosphoinositide. Abbreviations used: CaMKII, Ca 2 + /calmodulin-dependent protein kinase II; ECM, extracellular matrix; GDE, glycerophosphodiester phosphodiesterase; Glut2, glucose transporter 2; GroPIns, glycerophosphoinositol; GroPIns3P, glycerophosphoinositol 3-phosphate; GroPIns(3,4)P2, glycerophosphoinositol 3,4-bisphosphate; GroPIns(3,4,5)P3, glycerophosphoinositol 3,4,5-trisphosphate; GroPIns4P, glycerophosphoinositol 4-phosphate; GroPIns(4,5)P2, glycerophosphoinositol 4,5-bisphosphate; PLA2, phospholipase A2. 1 To whom correspondence should be addressed (email d.corda@ibp.cnr.it).
targeting, and are also the basis of the multiplicity of their functions. Within the cell, these specifically include GroPIns (glycerophosphoinositol) itself (Figure 1) , and its phosphorylated derivatives GroPIns4P (glycerophosphoinositol 4-phosphate) and GroPIns(4,5)P 2 (glycerophosphoinositol 4,5-bisphosphate).
Surprisingly, the glycerophosphoinositols have, for a long time, been the least studied of the phosphoinositide metabolites. They gained attention as potential active metabolites following the observation of robust increases in their intracellular levels in Ras-transformed epithelial cells [4, 8, 9] . Since then, the presence and potential activities of these different glycerophosphoinositols have become apparent in virtually all cell types and tissues analysed [1, 2] .
Metabolism of the glycerophosphoinositols
The intracellular levels of the glycerophosphoinositols have been monitored across a wide range of parental and transformed cells, as well as in differentiating cells [1, 2, 10, 11] . The intracellular concentrations of GroPIns have also been confirmed by MS [12, 13] , showing that it varies across different cell types in the range of low-micromolar to almost millimolar levels (from 40 to 900 μM), and it can be modulated according to the state of cell stimulation, activation, differentiation and transformation [1, 9, 11, [14] [15] [16] . On the other hand, the intracellular levels of GroPIns4P and GroPIns(4,5)P 2 are at least 10-and 100-fold lower respectively than that of GroPIns, as can be extrapolated from HPLC analysis following cell extraction after equilibrium labelling with [ 3 H]myo-inositol (see [10] and references therein).
Figure 1 GroPIns metabolism
Schematic representation of the formation of lysophosphatidylinositol (LysoPtdIns) and GroPIns from phosphatidylinositol (PtdIns) via two sequential steps, both of which are catalysed by PLA 2 IVα. The subsequent catabolism of GroPIns is then shown, as mediated by the GDEs (see the text for details). As indicated, PLA 2 IVα supports both of these deacylation steps, as demonstrated in in vitro investigations using purified phosphoinositide and lysophosphatidylinositol substrates together with the recombinant enzyme [3] . AA, arachidonic acid; FA, generic fatty acid. Modified with kind permission from Springer Science + Business Media: Cell. Mol. Life Sci., The glycerophosphoinositols: cellular metabolism and biological functions, 66, 2009, 3449-3467, Corda, D., Zizza, P., Varone, A., Filippi, B.M. and Mariggiò, S., Figure 1 .
In intact cells, the intracellular levels of the glycerophosphoinositols can be modulated by receptor stimulation and by calcium ionophores, and via the activation of a calcium-dependent PLA 2 [1, 3, 17] . As indicated, PLA 2 IVα has been shown to be specifically involved in stimulusdependent formation of GroPIns (Figure 1 ). This isoform of the PLA 2 superfamily can release arachidonic acid by hydrolysing the sn-2 ester of phosphoinositides, triggering the arachidonate pathway and leading to the synthesis and release of prostanoids and leukotrienes [3] . Importantly, PLA 2 IVα catalyses both of the deacylation steps that are necessary for the formation of the glycerophosphoinositols from their parent phosphoinositides, as has been shown by in vitro and whole-cell studies ( [3] and see legend to Figure 1) . Interestingly, this applies to agonist-induced formation of the glycerophosphoinositols in PLA 2 IVα-expressing cells; however, contributions from other phosphoinositidehydrolysing enzymes (e.g. other PLA 2 isoforms and lysolipases) might be involved in the maintenance of the basal levels of these compounds [1, 2, 10] . That this is the case became apparent in immortalized mouse lung fibroblasts [18] from PLA 2 IVα-knockout mice, where the steady-state intracellular levels of GroPIns are similar to those of control cells from wild-type mice [2] .
The catabolism of glycerophosphoinositols involves two members of the GDE (glycerophosphodiester phosphodiesterase) family, which mediate the hydrolysis of both basal and hormone-stimulated glycerophosphoinositols (Figure 1 ). These enzymes were initially identified in bacteria, and seven GDE isoforms have since been characterized in mammals [19, 20] . These GDEs have a highly conserved catalytic region of 56 amino acids [21] , and the substrate specificities and physiological functions are different for each isoform. In particular, GDE1 and GDE3 are the isoforms that show selectivity for the glycerophosphoinositols [19, 22] . GDE1 is an integral membrane glycoprotein that can hydrolyse GroPIns to form inositol and glycerol phosphate (Figure 1 ), and its catalytic domain is extracellular or intraluminal [21] . GDE1 was initially identified by yeast two-hybrid screening as a protein that can interact with RGS16, a regulator of G-protein signalling. Indeed, GDE1-mediated catabolism of GroPIns is regulated by G-protein-coupled receptors, such as the α/β-adrenergic and lysophospholipid receptors [21] . Similar to GDE1, GDE3 is also an ectoenzyme, although, in contrast with GDE1 and the bacterial enzymes, GDE3 specifically hydrolyses GroPIns to glycerol and Ins1P [22] ( Figure 1 ). In addition, whereas GDE1 is ubiquitously expressed, GDE3 is mainly expressed in osteocytes, and was first characterized as a marker of osteoblast differentiation [23] .
Among the other members of the GDE family, only cytosolic GDE5 is the isoform that is mainly expressed in skeletal and cardiac muscle [24, 25] . The glycerophosphoinositols are not substrates of GDE5, which instead preferentially hydrolyses glycerophosphocholine, as does GDE2, another member of the family that is widely expressed in the brain [26] .
Although the production of glycerophosphoinositols occurs mainly within the cell, as indicated in the present paper, their hydrolysis depends on GDEs that are enzymatically active in the extracellular space. Therefore the glycerophosphoinositols need to be released into the extracellular medium to undergo catabolism. This process occurs through a transporter that has been characterized in yeast (Git1p) [27] , whereas Glut2 (glucose transporter 2), a human orthologue of Git1p, has been shown to be involved in mammals [28] . Thus the glycerophosphoinositols can permeate the plasma membrane, possibly down local gradients following their acute production, and also following their exogenous addition. However, as Glut2 expression is restricted to some specific tissues (e.g. liver, kidney and small intestine [29] ), whereas the glycerophosphoinositols are formed and processed in all tissues, it is apparent that other Glut2-like transporters should also function in cells; these have yet to be identified.
Biological activities of the glycerophosphoinositols
The discovery of a possible link between the formation of glycerophosphoinositols and Ras activation [4, 30] led to investigations of the biological activities of these compounds, initially in Ras-dependent pathways (Figure 2 ). These Rasdependent pathways are known to have important functions in many cellular events, such as cell proliferation, motility and invasion [31, 32] .
In a normal rat thyroid cell line (FRTL5 cells) where growth and differentiation are mainly regulated by the adenylate cyclase cascade [33] , exogenously added GroPIns4P [but not GroPIns or GroPIns(4,5)P 2 ] can inhibit the accumulation of cAMP in a dose-dependent manner, through the inhibition of adenylate cyclase activity [34] . As a consequence, the cAMP-dependent functions, such as iodide uptake and cell growth, are also inhibited [34] . GroPIns4P-dependent inhibition of adenylate cyclase was also observed in other cell lines, including RBL (rat basophilic leukaemia) cells and fibroblasts [17] . In a different thyroid cell model (rat PCCl3 cells), GroPIns has been shown to stimulate TSH (thyroid-stimulating hormone)-independent cell growth [3] . This occurs when GroPIns is added exogenously, or upon GroPIns production, following stimulation of α 1 -adrenergic, α 2 -adrenergic or P2Y purinergic receptors [3] . Adrenergic and purinergic regulation of thyroid functions has been well documented [35] ; these data have suggested that the receptor-activated PLA 2 IVα controls thyroid cell proliferation through a transient GroPIns production, rather than through the arachidonic acid cascade, both originating from the phosphoinositide hydrolysis [3] . A similar effect of GroPIns on cell proliferation has been reported in an osteoblast cell line (MC3T3 cells [22] ), in which the GDE3 expression levels account for the catabolism of GroPIns. In osteoblasts, as in other cell systems, the control pathways of proliferation and differentiation are strictly coupled [22] . An increase in GDE3 activity is sufficient to promote disassembly of actin stress fibres, a decrease in cell growth rate and an increase in alkaline phosphatase activity and intracellular Ca 2 + levels. These findings indicate a role for GDE3 in the induction of differentiation. Consequently, GroPIns emerges as a candidate mediator for osteoblast proliferation, in line with the GroPIns activity observed in epithelial cells [3] .
In addition to the effects of the glycerophosphoinositols on cell proliferation, also cell motility and invasiveness are modulated by these phosphoinositide metabolites [36] [37] [38] . All of these events require modifications of the structure of the actin cytoskeleton, and indeed, when GroPIns4P is added exogenously to Swiss3T3 fibroblasts, it induces the reorganization of the actin cytoskeleton, with the formation of membrane ruffles and stress fibres; this has been shown to occur through activation of the monomeric GTPases Rac1 and RhoA respectively [39] . GroPIns and GroPIns(4,5)P 2 can also activate Rac1, but less efficiently and in a very transient manner, which is not compatible with effects on the organization of the actin cytoskeleton [39] . This activation of Rho proteins by GroPIns4P is not due to a direct action at the level of these GTPases. This has been demonstrated in NIH 3T3 mouse fibroblasts, where GroPIns4P triggers a signalling cascade that starts from Src kinase phosphorylation, and through activation of phospholipase Cγ and CaMKII (Ca 2 + /calmodulindependent protein kinase II), leads to plasma membrane translocation of Tiam1, a specific GTPase exchange factor for Rac1. This process induces the formation of membrane ruffles via Rac1 activation at the plasma membrane [36] . The essential role of the Src/phospholipase Cγ /CaMKII pathway in GroPIns4P-induced ruffle formation was clearly indicated by the lack of effects of GroPIns4P in SYF cells (embryonic fibroblasts that do not express the three ubiquitously expressed Src isoforms: Src, Fyn and Yes [40] ). Moreover, ruffle induction by GroPIns4P can be rescued in SYF cells upon overexpression of Src, demonstrating the direct link between GroPIns4P and the Src cascade [36] .
This role of the glycerophosphoinositols in the regulation of the organization of the actin cytoskeleton that was characterized in fibroblasts has also been reported in lymphocytes. In Jurkat T-cells (human leukaemia T-lymphocytes) and, more interestingly, in peripheral blood lymphocytes from healthy donors, exogenously added GroPIns4P increases phosphorylation, and consequently activation, of Vav1, the main guanine-nucleotide-exchange factor for Rac1 in leucocytes, which results in actin polymerization [37] . In these cells, GroPIns4P has been shown to enhance CXCR4 (CXC chemokine receptor 4)-dependent chemotaxis. At the molecular level, this GroPIns4P effect results from its activation of Vav1, which occurs through a pathway that is dependent on lymphocyte-specific protein tyrosine kinase (Lck); this conclusion is also supported by the failure of GroPIns4P to trigger Vav phosphorylation in Lck-deficient (JCaM1) cells [37] . In the same study, GroPIns4P was found to mediate (with delayed kinetics) Lck-dependent activation of a signal cascade that includes ZAP-70 [ζ -chain (T-cell receptor)-associated protein kinase of 70 kDa], Shc, p38 and ERK (extracellular-signal-regulated kinase) 1/2 [37] .
Again in lymphocytes, GroPIns4P has been shown to have potent modulatory effects on cell proliferation and activation induced by T-cell-receptor stimulation (L. Patrussi, personal communication). These data clearly show a role for the glycerophosphoinositols as modulators of T-cell signalling, and they establish a mechanistic basis for the effects of GroPIns4P on F-actin (filamentous actin) dynamics. This has pathophysiological relevance, as, through their potent PLA 2 activity, a number of haemopoietic cells can produce large amounts of the glycerophosphoinositols in response to proinflammatory stimuli [1] . Among these cells, there are the antigen-presenting cells, which can produce and release the glycerophosphoinositols into their extracellular medium, which may then act as paracrine factors for lymphocytes [2, 37] .
The ability of the glycerophosphoinositols to modulate Rho protein function was exploited also in relation to the ability of tumour cells to migrate towards a chemoattractant, and to invade the ECM (extracellular matrix) [38] . Treatment of A375MM (human melanoma) and MDA-MB-231 (human mammary carcinoma) cells with GroPIns and GroPIns4P can inhibit their migration through the ECM. Here, tumour invasion implies two distinct events: (i) degradation of the ECM, and (ii) migration of the cells. Treatment with the glycerophosphoinositols reduces the ECM degradation of both of these tumour cell lines (as shown in in vitro assays of gelatin degradation) [38] . However, the ability of these tumour cells to follow a chemotactic gradient (cell migration) is not significantly affected by these glycerophosphoinositols. In this context, it was suggested that the glycerophosphoinositols affect the formation of invadopodia, the specialized cellular structures that are dedicated to ECM degradation [41] . Indeed, treatment of invasive tumour cells with GroPIns and GroPIns4P reduces both the number of degradation sites and the number of invadopodia, without significantly affecting the structural and signalling components of invadopodia [38] . However, a full mechanistic definition of GroPIns-induced and GroPIns4P-induced impairment of ECM degradation in these tumour cells needs further investigation, although this experimental evidence highlights the pharmacological potential of the glycerophosphoinositols in the treatment of tumours.
The information gathered to date underlines a clear difference between the biological functions of GroPIns and GroPIns4P. This will probably derive from their different effects on different cellular targets. However, although no direct targets for glycerophosphoinositols have been identified to date, a proteomics approach has been used that demonstrates this potential for a series of cytosolic proteins; these are now under characterization as specific GroPIns and GroPIns4P targets (A. Varone, unpublished work).
The phosphorylated glycerophosphoinositols
GroPIns and GroPIns4P are the most abundant glycerophosphoinositols in the cell [10] . The phosphorylation/ dephosphorylation pathways of the phosphoinositides include, however, seven phosphatidylinositol species that are Table 1 Biological activities of GroPIns4P and the 3-phosphorylated glycerophosphoinositols
The Table summarizes the effects of GroPIns4P and of the 3-phosphorylated glycerophosphoinositols in the indicated assays as detailed below. For details of the adenylate cyclase assay, see the method in [34] . Briefly, membranes from KiKi or Swiss 3T3 cells were pre-incubated for 10 min at 37 • C in the absence and presence of the glycerophosphoinositols at the indicated concentrations. The adenylate cyclase activities were then stimulated by the addition of 10 − 7 M cholera toxin (KiKi cells) or 2 μM AlF 4 − (Swiss3T3 cells) for 1 h at 37 • C. Results are expressed as mean ± S.E.M.
percentages of stimulated control samples for four independent experiments, each performed in duplicate. AC, adenylate cyclase; CTX, cholera toxin. For details of the chemotaxis and chemoinvasion assays, see the methods in [38] . Briefly, MDA-MB-231 cells were seeded into a modified Boyden chamber that was either uncoated (migration) or coated (invasion) with Matrigel TM . During the assay (16 h migration, 6 h invasion), the cells were in the absence or presence of 100 μM of the indicated glycerophosphoinositols. Results are means ± S.E.M. for three independent experiments, each performed in duplicate. For details of the analysis of actin cytoskeleton modifications, see the methods in [36] . Briefly, NIH 3T3 fibroblasts were plated on coverslips, serum-deprived for 16 h, and then treated with 50 μM of the glycerophosphoinositols. At the end of the incubation, the cells were fixed, stained with fluorescent phalloidin and analysed under confocal microscopy. The quantification shows the mean ± S.D. percentages of cells with ruffles or stress fibres, and the time points at which the maximum effects were reached in time-course assays (from 0 up to 20 min), for three independent experiments, each performed in duplicate. The synthetic 3-phosphorylated glycerophosphoinositols were prepared starting from their respective inositol phospholipids as follows: phosphorylated inositol phospholipid [10 mg, e.g. dioctanoyl-PtdIns(3,4)P 2 ] was sonicated in water (5 ml) to obtain a near-translucent dispersion. Aqueous ammonia (10 M, 1 ml) was added next, and the mixture was kept at room temperature, while monitoring the progress of the hydrolysis reaction by 31 P-NMR. After all of the substrate had been cleaved (typically at 24 h), the mixture was evaporated to dryness under vacuum. The residue was resuspended in water (5 ml), acidified to pH 5 (with HCl), and extracted with chloroform/methanol (2:1, v/v, 3×2 ml). The aqueous phase was separated from the organic phase, concentrated and dried, and the product was redissolved in water (10 ml). This solution was passed through a C 16 -silica gel column, and the eluate was concentrated to give a white-to-yellowish solid on drying. phosphorylated at different positions of the inositol ring and these inositol phospholipids could serve as precursors of the corresponding glycerophosphoinositols, as is the case across the range of inositol phosphates that can be found in the cell. Again, as with inositol phosphates [42] , as well as the biological actions of GroPIns and GroPIns4P described above, these other phosphorylated forms of GroPIns might also be able to modulate cell function through actions on specific targets with different specificities and potencies. However, the 3-phosphorylated glycerophosphoinositols [GroPIns3P (glycerophosphoinositol 3-phosphate), GroPIns(3,4)P 2 (glycerophosphoinositol 3,4-bisphosphate) and GroPIns(3,4,5)P 3 (glycerophosphoinositol 3,4,5-trisphosphate)] have not been seen in cells in a physiological context; indeed, as their cellular levels would be expected to be at least 100-1000-fold lower than that of GroPIns4P, this creates challenges for monitoring and measuring of these compounds in the cell. For this reason, and to be able to determine any potential function of these putative intracellular glycerophosphoinositols, we have investigated the synthetic 3-phosphorylated GroPIns derivatives GroPIns3P, GroPIns(3,4)P 2 and GroPIns(3,4,5)P 3 in a range of relevant functional assays (Table 1) .
First, the ability of these compounds to modulate adenylate cyclase activity was evaluated, and compared with the previously shown inhibitory activity of GroPIns4P in membranes of K-Ras-transformed thyroid (KiKi) cells [34] . In these cell membranes, GroPIns(3,4)P 2 and GroPIns(3,4,5)P 3 inhibited cholera toxin-stimulated adenylate cyclase activity (for methods, see Table 1 and [34] ). Similar data were obtained in membranes from Swiss 3T3 fibroblasts upon stimulation of adenylate cyclase with aluminium fluoride [43] . Differently from GroPIns4P, GroPIns3P showed a biphasic effect: it acted as an activator of basal and low-levels of adenylate cyclase activity (in the presence of aluminium fluoride), but it had an inhibitory effect in the presence of pronounced activation of adenylate cyclase induced by cholera toxin ( Table 1) .
The potential effects of GroPIns3P, GroPIns(3,4)P 2 and GroPIns(3,4,5)P 3 on actin cytoskeleton organization were also tested and compared with the previous results for GroPIns4P [39] . All synthetic 3-phosphorylated glycerophosphoinositols induced ruffles in NIH 3T3 cells, with GroPIns(3,4,5)P 3 being the most potent in stimulating stress fibre formation (Table 1) .
None of the synthetic 3-phosphorylated glycerophosphoinositols, however, inhibited chemotaxis in the above-mentioned A375MM and MDA-MB-231 cancer cells lines, although GroPIns(3,4,5)P 3 induced a 40% inhibition in their chemoinvasion assays (for methods, see Table 1 and [38] ).
In summary, the above results clearly suggest potential activities for 3-phosphorylated glycerophosphoinositols in the cells. However, as indicated above, mechanistic studies of cellular roles for these glycerophosphoinositol species are hampered by the difficulties in monitoring their cellular levels, and by the costly procedures used to obtain the synthetic compounds. Altogether, these data serve as proofof-principle that not only GroPIns and GroPIns4P, but also other phosphorylated glycerophosphoinositol species could constitute potentially active metabolites arising from phosphoinositide metabolism. Further studies across this full range of phosphorylated glycerophosphoinositols should uncover the wide and multiple activities of the various inositol phosphates. This will then lead to a better understanding of the metabolism, regulation and function of the inositol phospholipids, glycerophosphoinositols and inositol phosphates in the cells.
